JP2004532849A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532849A5
JP2004532849A5 JP2002583620A JP2002583620A JP2004532849A5 JP 2004532849 A5 JP2004532849 A5 JP 2004532849A5 JP 2002583620 A JP2002583620 A JP 2002583620A JP 2002583620 A JP2002583620 A JP 2002583620A JP 2004532849 A5 JP2004532849 A5 JP 2004532849A5
Authority
JP
Japan
Prior art keywords
composition
polynucleotide
tissue
agent
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002583620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/012527 external-priority patent/WO2002086105A1/en
Publication of JP2004532849A publication Critical patent/JP2004532849A/ja
Publication of JP2004532849A5 publication Critical patent/JP2004532849A5/ja
Pending legal-status Critical Current

Links

JP2002583620A 2001-04-20 2002-04-19 中枢神経系へのポリヌクレオチド薬剤の送達 Pending JP2004532849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28531901P 2001-04-20 2001-04-20
US28871601P 2001-05-04 2001-05-04
PCT/US2002/012527 WO2002086105A1 (en) 2001-04-20 2002-04-19 Delivery of polynucleotide agents to the central nervous sysstem

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008282272A Division JP2009067805A (ja) 2001-04-20 2008-10-31 中枢神経系へのポリヌクレオチド薬剤の送達

Publications (2)

Publication Number Publication Date
JP2004532849A JP2004532849A (ja) 2004-10-28
JP2004532849A5 true JP2004532849A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=26963130

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002583620A Pending JP2004532849A (ja) 2001-04-20 2002-04-19 中枢神経系へのポリヌクレオチド薬剤の送達
JP2008282272A Withdrawn JP2009067805A (ja) 2001-04-20 2008-10-31 中枢神経系へのポリヌクレオチド薬剤の送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008282272A Withdrawn JP2009067805A (ja) 2001-04-20 2008-10-31 中枢神経系へのポリヌクレオチド薬剤の送達

Country Status (4)

Country Link
US (3) US20030165434A1 (cg-RX-API-DMAC10.html)
EP (1) EP1385937A4 (cg-RX-API-DMAC10.html)
JP (2) JP2004532849A (cg-RX-API-DMAC10.html)
WO (1) WO2002086105A1 (cg-RX-API-DMAC10.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423537A4 (en) * 2001-08-07 2006-11-29 Univ Delaware COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HUNTINGTON'S DISEASE
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
EP1597366B1 (en) 2003-02-11 2012-11-21 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
EP1711509A4 (en) * 2004-01-23 2009-08-26 Oklahoma Med Res Found INHIBITION OF THE BRIGHT FUNCTION AS A TREATMENT OF EXCESSIVE IMMUNE LOBULIN FORMATION
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP5144267B2 (ja) * 2004-10-28 2013-02-13 アイデックス ラボラトリーズ,インコーポレイティド 医薬活性化合物を制御して搬送するための組成物
US20060165739A1 (en) * 2005-01-06 2006-07-27 Mary Kay Inc. Alcohol-free microemulsion composition
AU2006247215B2 (en) * 2005-05-18 2012-09-13 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for real-time nucleic acid analysis in live cells
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
JP2009515962A (ja) * 2005-11-16 2009-04-16 アイデックス ラボラトリーズ,インコーポレイティド アプタマー投与のための医薬組成物
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
WO2008112807A1 (en) * 2007-03-12 2008-09-18 Sarentis Therapeutics, Inc. Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
WO2010009015A2 (en) * 2008-07-14 2010-01-21 Oklahoma Medical Research Foundation Production of pluripotent cells through inhibition of bright/arid3a function
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
DK2734634T3 (da) * 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne
US9486540B2 (en) * 2012-03-09 2016-11-08 Northeastern University Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
EP2967817B1 (en) 2013-03-12 2021-03-10 Oculeve, Inc. Implant delivery devices and systems
CN108744272A (zh) 2013-04-19 2018-11-06 奥库利维公司 鼻刺激装置和方法
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
RU2698711C2 (ru) 2014-02-25 2019-08-29 Окулив, Инк. Составы полимеров для носослёзной стимуляции
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
EP3673952A1 (en) 2014-07-25 2020-07-01 Oculeve, Inc. Stimulation patterns for treating dry eye
KR20170074926A (ko) 2014-10-22 2017-06-30 오큘레브, 인크. 안구 건조증을 치료하기 위한 자극 장치 및 방법
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
AU2015335772B2 (en) 2014-10-22 2020-07-09 Oculeve, Inc. Contact lens for increasing tear production
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
EP3547898A4 (en) 2016-12-02 2020-07-08 Oculeve, Inc. APPARATUS AND METHOD FOR PREDICTING EYE DROUGHT AND TREATMENT RECOMMENDATION
CN109498832B (zh) * 2017-09-15 2021-10-08 中国药科大学 一种交联多孔止血微球及其制备方法
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
JP2022547948A (ja) 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
US20230304012A1 (en) * 2019-10-16 2023-09-28 Brown University Muscle regeneration and growth
JP2023181674A (ja) * 2022-06-13 2023-12-25 国立大学法人 東京大学 核酸とカチオン性ポリマーとのポリイオンコンプレックスであって、正の表面電位を有し、核酸を脳組織に送達することができるポリイオンコンプレックス

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5714170A (en) * 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6025193A (en) * 1996-03-15 2000-02-15 Allegheny University Of The Health Sciences Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines

Similar Documents

Publication Publication Date Title
Vitek et al. APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer’s disease transgenics
US11000572B2 (en) Composition having tissue-repairing activity, and use therefor
US5281607A (en) Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases
JP5383498B2 (ja) メラノコルチン4レセプターの活性を低下させる薬剤を使用した、神経系の疾患または損傷の処置
RU2016118528A (ru) Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna
CA2539596A1 (en) Melanocortin receptor agonists
JP2009067805A (ja) 中枢神経系へのポリヌクレオチド薬剤の送達
JP6889154B2 (ja) グルカゴン類似ペプチド−1受容体亢進剤を含む筋減少症治療用薬学組成物
CN108289932A (zh) 胞外dna作为神经变性的治疗靶点
US9486540B2 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
JP2024543214A5 (cg-RX-API-DMAC10.html)
JP2012197290A (ja) Igfの構造的アナログを投与することによる中枢神経系の治療方法
JP5481762B2 (ja) 脳移行性機能性核酸及びその利用
US20130197069A1 (en) Methods for treating stress induced emotional disorders
Wu et al. Deciphering the skeletal interoceptive circuitry to control bone homeostasis
KR20120018122A (ko) 신경 손상 및 신경변성 질환 후 신경학상 결과를 개선하는 방법
EP1235858A1 (en) Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders
US20220127347A1 (en) Inhibition of Tau Propagation
DE602004008085T2 (de) Antisense-oligonukleotid zur hemmung der melanom-inhibierenden aktivität (mia)
Ruxin et al. ECT in combined multiple system atrophy and major depression
US7396823B2 (en) Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
JP5784754B2 (ja) 神経疾患の予防または処置のためのicam−1の使用
JP7792727B2 (ja) アミロイド前駆体タンパク質に対する阻害活性を有するペプチドおよびその用途
CN118900844A (zh) 用于溶解蛋白质聚集体的肽和其方法
CN121729494A (zh) 治疗肺纤维化的方法